Objectives: Discrepancies between inflammatory bowel disease (IBD) endoscopic/histological extent are documented at diagnosis. It is unclear whether these differences persist through disease course, with potential impact on categorization and management. We aimed to analyze the progression of disease over a 3-year period. Methods: Patients younger than 17 years, diagnosed between 2010 and 2013 at Southampton Children's Hospital and followed-up for 3 years were eligible. Primary outcome was disease extent at diagnosis and follow-up. Data are presented as percentage of patients undergoing endoscopy. Paris classification (PC) and PC using histological, rather than endoscopic disease, were determined. Results: One hundred and twenty-five patients were included, 66 boys; Crohn's disease (CD) 74, ulcerative colitis (UC) 40, IBD unclassified (IBDU) 11. All had endoscopy at diagnosis. One hundred and two patients underwent !1 repeat endoscopies. Disease extent reduced from diagnosis to first follow-up endoscopy for both endoscopic and histological disease extent (CD/UC/IBDU, all P < 0.00006). Histological extent remained greater than endoscopic in CD with significant differences in stomach, ileum, and large bowel at all follow-up points (P ¼ < 0.045). Endoscopic matched histological extent in UC/IBDU. Applying a modified PC resulted in significant changes for CD (L3 27.4%À53.2%, P ¼ 0.006, L3 þ L4A 21%À50%, P ¼ 0.001, and upper gastrointestinal disease 50%-80.6%, P ¼ 0.0006) but not UC. CD height (À0.37 to À0.25) and weight (À1.09 to À0.19) standard deviation scores increased from diagnosis to follow-up. Conclusions: Histological disease is greater than endoscopic extent at diagnosis and during follow-up in CD, although not in UC/IBDU. Classification of disease extent in CD should be based on both endoscopic and histological criteria.
P
aediatric inflammatory bowel disease (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC), and inflammatory bowel disease unclassified (IBDU) is a chronic, relapsing condition typically presenting with severe and extensive disease in children (1, 2) .
The progression of both endoscopic and histological disease in relation to treatment is likely to be valuable to better understand the efficacy of treatment, and in particular to assess disease control by observing if mucosal healing is achieved (3, 4) . The impact of newer therapies on mucosal healing, growth, and relapse rates appear positive but further data are needed in paediatric cohorts (5) . There is increasing interest in the differences between endoscopic and histological disease extent (2, 6, 7) . It is now accepted that histological disease is far more extensive than endoscopic disease extent at diagnosis; however, only Paris classification (PC) of endoscopic disease is a validated tool for subclassification of disease and it does not consider histological disease (8) . Endoscopic and histological disease extent from diagnosis through follow-up (FU) is less well documented with studies focusing on PC in isolation (9) (10) (11) . If mucosal healing is the aim of therapy then it is important that patients are not ''underclassified'' based on endoscopic findings only as this may lead to undertreatment.
In this study, we detail the 3-year FU from diagnosis of a previously described cohort of patients with PIBD and analyse the endoscopic and histological disease progression and assess any differences between endoscopic and histological disease extent over this time period. We apply a modified PC of disease based only on histological disease extent to these data (excluding small bowel imaging).
What Is Known
In paediatric inflammatory bowel disease severity and extent of disease influences management. Discrepancies between endoscopic disease extent and histological disease extent are documented at diagnosis but it is unknown if these persist through the disease course.
What Is New
Histological disease extent is greater than endoscopic extent during follow-up in Crohn's disease, but this is not in observed in ulcerative colitis or inflammatory bowel disease unclassified. It may be helpful for classification of disease extent in Crohn's disease to be based on both endoscopic and histological criteria, a modified Paris classification.
METHODS
Patients were identified from the Paediatric Gastroenterology service database at Southampton Children's Hospital. All patients had previously been studied at diagnosis and were selected for inclusion in this study based on these criteria (2) . Patients were diagnosed from January 1, 2010 to December 31, 2013. All were younger than 17 years at the point of diagnosis and all were diagnosed according to the Porto criteria (12) with IBDU patients categorized according to revised Porto criteria and European Society of Paediatric Gastroenterology, Hepatology and Nutrition/North American Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN/NASPGHAN) guidelines (13) . The most up to date diagnostic criteria was used at each time point.
Data for a 3-year FU period were collected by 2 individuals (J.J.A., Q.B.) on a standardized pro forma and all were crosschecked by the second clinician. Repeat endoscopy was performed for consideration of treatment escalation or assessment of the efficacy of anti-tumor necrosis factor agents in patients on these treatments. All endoscopic and histological data were collected from prospectively entered standardized electronic records at Southampton Children's Hospital. Where patients had undergone >2 endoscopies during the FU period the first and last endoscopy data were analysed. Disease extent at diagnosis was compared to disease extent at first and most recent FU endoscopy. Treatment and surgical data were collected for each treatment/surgery used in the FU period from electronic clinic records. Growth data were collected from 2.5 to 3.5 years after diagnosis. Radiological data were not examined in the present study.
Endoscopic disease extent was determined by a group of 4 paediatric gastroenterologists (R.M.B., N.A., T.C., A.B.) in line with PC (8) . A standardized system of taking biopsies was applied; 2 oesophageal, 2 gastric (including antral), and 2 duodenal biopsies plus 3 to 4 ileal biopsies and a colonic series (from caecum to rectum) of >8 biopsies. Histological diagnosis was based on the presence of inflammatory changes in the mucosa (acute or chronic gastritis/duodenitis/oesophagitis, cryptitis, crypt abscesses, and granulomas), architectural abnormalities (crypt distortion, crypt branching, and crypt atrophy), and epithelial abnormalities such as mucin depletion and metaplasia, alongside surface irregularities (epithelial active/regenerative changes).
The primary outcome was percentage of patients with endoscopic or histological disease at a specific location. Secondary outcomes were percentage of patients with a specific PC/modified PC.
This retrospective study was approved and registered with the Clinical Effectiveness and Governance teams at the University Hospital Southampton NHS trust. Data are presented as percentage of patients undergoing endoscopy to that anatomical location (restriction of procedure results in more distal location data than proximal data). Statistical analysis was conducted using Fisher exact test (SPSS v23, IBM, Armonk, New York, USA).
RESULTS
Of 172 eligible patients identified, 125 were included and followed up. All 47 excluded patients had transitioned to adult services or moved out of area within the 3-year FU period (Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/ MPG/B100). Median age at diagnosis 12.5 years, 66 boys; CD 74, UC 40, IBDU 11. A single patient initially classified at UC was rediagnosed at CD following further investigations (12) .
The mean time to first repeat endoscopy was 1.2 years for CD, 1.9 years for UC, and 1.9 years for IBDU. Five patients (1 CD, 3 UC, and 1 IBDU) underwent lower gastrointestinal (GI) endoscopy only. Ileoscopy was achieved in 84% of patients undertaking colonoscopy.
Crohn's Disease
Sixty-two patients had !1 FU endoscopy, 39 had !2 FU endoscopies.
Upper Gastrointestinal Endoscopy
At first FU endoscopy there was endoscopic involvement of the oesophagus in 9.8%, the stomach 37.7%, and the duodenum 27.9%. Histological involvement of the oesophagus was seen in 24.6%, the stomach in 78.7%, and the duodenum in 24.6%.
At most recent FU endoscopy (mean time from diagnosis, 2.3 years) there was endoscopic involvement of the oesophagus in 10.5%, the stomach 15.8%, and the duodenum 18.4%. Histological involvement of the oesophagus was observed in 28.9%, the stomach 71.1%, and the duodenum 18.4% (Table 1) .
Lower Gastrointestinal Endoscopy
At first FU endoscopy there was endoscopic involvement of the rectum in 53.2%, descending colon 53.2%, transverse colon 45.9%, and the ascending colon 47.5%. There was ileal disease in 46.5%. Histological involvement of the rectum was seen in 71%, the descending colon 71%, the transverse colon 72.6%, and the ascending colon 72.1%. There was histological ileal disease in 78.4% of patients.
At most recent FU endoscopy endoscopic involvement of the rectum was observed in 38.5%, descending colon 41%, transverse colon 25.7%, and the ascending colon 29.4%. There was ileal disease in 25%. Histological involvement of the rectum was seen in 69.2%, the descending colon 69.2%, the transverse colon 62.9%, and the ascending colon 62.9%. There was histological ileal disease in 66.7% (Table 1) .
Disease Progression
Disease extent reduced from diagnosis to first and most recent FU endoscopy for both endoscopic disease extent and histological disease extent at all sites (excluding the duodenum) ( Table 2 ). Despite overall disease extent reducing there was increased discrepancy between endoscopic and histological disease from diagnosis through to most recent FU. This was most pronounced throughout the lower GI tract (Tables 1 and 2 ).
Paris Classification
The PC of disease was applied to endoscopic and histological disease location as previously described (2) . A (modified) histological PC demonstrated a statistically significant increase of 25.8% in total L3 disease (P ¼ 0.006), a statistically significant increase of 29% in L3 þ L4A disease (P ¼ 0.001), and a statistically significant increase of 30.6% in total upper GI involvement (L4 disease) (P ¼ 0.0006), as compared to endoscopic PC (Table 3) . 
Medications
At initial FU endoscopy (n ¼ 62 patients) 41.9% of patients were on a 5-aminoaminosalicylic acid (5ASA) preparation, 56.5% a thiopurine, 3.2% a biological agent, and 9.7% on no maintenance medication; 19.4% were on 2 maintenance medications. At most recent FU endoscopy (n ¼ 39 patients) 41.0% of patients were on a 5ASA preparation, 79.5% a thiopurine, 61.5% a biological agent, and 5.1% were on no maintenance medication; 74.4% were on 2 maintenance medications.
At 3-year FU (74 patients), 47.3% of all patients were on a biological agent (mean time to commencing treatment from diagnosis, 1.3 years). During FU 53.4% of patients had been on/are currently on a 5ASA preparation (mean time to starting from diagnosis, 0.4 years) and 85.1% had been on/are currently on a thiopurine agent (mean time to starting from diagnosis, 0.6 years).
During FU 14 patients underwent surgery (23.3%), 10 of these procedures were resections and 4 were perianal (seton placement, etc).
Predictors of Disease Extent
The presence of granuloma at diagnosis was assessed as a predictor for disease outcome (histological or endoscopic disease extent). Supplementary Table 1 (Supplemental Digital Content 2, http://links.lww.com/MPG/B101). Granuloma seen at diagnosis was associated with more extensive histological colonic disease (P ¼ 0.024) but not endoscopic disease at FU.
Ulcerative Colitis
Thirty patients had !1 FU endoscopy, 12 had !FU 2 endoscopies.
Upper Gastrointestinal Endoscopy
At first FU endoscopy there was endoscopic involvement of the oesophagus in 10.7%, the stomach in 10.7%, and the duodenum in 10.7% of patients. There was histological involvement of the oesophagus in 7.4%, the stomach 33.3%, and the duodenum 3.7%. At most recent FU endoscopy (mean time from diagnosis, 2.9 years) endoscopic involvement of the oesophagus was seen in 9.1%, the stomach 9.1%, and the duodenum 27.3%. Histological involvement of the oesophagus was observed in 18.2%, the stomach 27.3%, and the duodenum 27.3% (Table 1) .
Lower Gastrointestinal Endoscopy
At first FU endoscopy there was endoscopic involvement of the rectum in 66.7%, descending colon in 56.7%, transverse colon 
Statistical significance not calculated if patient group <11 or difference <5%. Values expressed as percentage of patients with disease that underwent endoscopy to that anatomical location for endoscopic disease (number of patients) and percentage patients with disease on histology for histological disease (number of patients).
Bold signifies significant at a value of P < 0.05. FU ¼ follow-up; GI ¼ gastrointestinal. 54.5% (6) 20% (2) À34.5
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50% (2)
À36.7
93.3% (14) 60% (6) À33.3
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Cumulative P in 30%, and the ascending colon in 23.3%. No patients had ileal disease. Histological involvement of the rectum was seen in 65.5%, the descending colon 39.3%, the transverse colon 31.1%, and the ascending colon 27.6%. Histological ileal disease was observed in no patients. At most recent FU endoscopy there was endoscopic involvement of the rectum in 83.3%, descending colon 66.7%, transverse colon 58.3%, and the ascending colon 41.7%. Ileal disease was rare, seen in 9.1% of patients. There was histological involvement of the rectum in 100%, the descending colon 83.3%, the transverse colon 58.3%, and the ascending colon 41.7%. Histological ileal disease was observed in 9.1% (Table 1) .
Standard deviation scores at diagnosis and 3-year follow-up in Crohn's disease. Data at diagnosis taken from Ashton et al (14) .
Disease Progression
Disease extent reduced from diagnosis to initial FU endoscopy for both endoscopic disease extent and histological disease extent at all sites (excluding the oesophagus and duodenum). At most recent FU endoscopic disease extent was less than at diagnosis and highly comparable to initial FU (with moderately greater lower GI disease extent). Upper GI histological disease extent was generally greater at most recent FU, whereas lower GI disease was highly comparable to initial FU (Table 2) .
Paris Classification
The PC of disease was applied to endoscopic and histological disease location as previously described (2) . Modified histological PC demonstrated an increase of 14.5% in total E1 disease and an increase of 7.6% in E4 disease, as compared to endoscopic PC (Table 3) .
Growth
FU growth data (height, weight, and BMI SDS) were available for 35 of 40 (87.5%). At diagnosis the median height SDS 0.53, median weight SDS 0.14, and BMI SDS 0.36. At FU median height SDS 0.33, median weight SDS 0.96, and median BMI SDS 1.02.
Medications
At first FU endoscopy (n ¼ 30 patients) 70% of patients were on a 5ASA preparation, 53.3% a thiopurine, 3.3% a biological agent, and 16.7% were on no maintenance medication; 43.3% were on 2 maintenance medications. At the most recent FU endoscopy (n ¼ 12 patients) 41.7% of patients were on a 5ASA preparation, 58.3% a thiopurine, 16.7% a biological agent, and 16.7% were on no maintenance medication; 50% were on 2 maintenance medications. During FU 2 patients underwent surgery (6.7%), both procedures were resections.
Inflammatory Bowel Disease Unclassified
Ten patients had !1 FU-endoscopy (9 had undergone upper GI endoscopy), 4 had !2 FU endoscopies.
Upper Gastrointestinal Endoscopy
At first FU upper GI endoscopy (n ¼ 9) there was endoscopic involvement of the oesophagus in 11.1%, the stomach in 37.5%, and the duodenum in 22.2% of patients. There was histological involvement of the oesophagus in 11.1%, the stomach in 11.1%, and the duodenum in no patients (Table 1) . Most recent FU data (for 4 patients undergoing a second endoscopy) can be seen in Table 1 .
Lower Gastrointestinal Endoscopy
At first FU lower GI endoscopy (n ¼ 10) there was endoscopic involvement of the rectum in 30%, descending colon in 30%, transverse colon in 20%, and the ascending colon in 20% of patients. No ileal disease was seen. There was histological involvement of the rectum in 60%, the descending colon in 40%, the transverse colon in 30%, and the ascending colon in 40% of patients. Histological ileal disease was observed in 20% of patients (Table 1) . Most recent FU data (for 4 patients undergoing a second endoscopy) can be seen in Table 1 .
Disease Progression
Disease extent reduced from diagnosis to initial FU endoscopy for both endoscopic disease extent and histological disease extent at all sites (excluding the duodenum) ( Table 2) .
Growth
FU growth data (height, weight, and BMI SDS) were available for 11/12 (91.7%) patients. At diagnosis the median height SDS was 0.08, median weight SDS was À0.15, and BMI SDS was À0.08. At FU median height SDS was À0.05, median weight was SDS 0.04, and median BMI SDS was À0.16.
Medications
At initial FU endoscopy (n ¼ 10 patients) 50% of patients were on a 5ASA preparation, 50% a thiopurine, none were on a biological agent, and 20% were on no maintenance medication; 20% were on 2 maintenance medications. At the most recent FU endoscopy (n ¼ 4 patients) no patients were on a biological therapy.
DISCUSSION
FU data in PIBD patients is vital to plan and assess response to treatment, with a potential shift towards achieving mucosal healing as a true definition of remission (15, 16) . The present study demonstrates statistically significant reductions in both endoscopic and histological disease extent from diagnosis to all FU points in CD, UC (excluding endoscopic disease at second FU) and IBDU. Less extensive disease throughout the GI tract demonstrates effective treatment leading to macroscopic and microscopic healing. However in CD there are still areas of the bowel with significant active disease, and there is a discrepancy between endoscopic and histological disease extent, which increases from diagnosis through FU. The lower GI tract has high levels of histological involvement at FU (ileal disease in 66.7%-78.4% of patients and colonic disease in 62.9%-72.6% of patients). This histological extent is not captured by the PC and increased with time leading to potentially underreported disease extent during FU.
This discrepancy is less evident in UC and IBDU at FU compared to diagnosis (Table 1) . In CD there are, however, statistically significant increases in disease extent in the stomach, ileum, and throughout the large bowel at all time points studied, compared to diagnosis. It is possible that this reflects the transmural and systemic inflammation seen in CD not observed in UC or IBDU. Granulomatous disease (upper or lower GI) was present in 66.1% of initial FU endoscopy cases and 56.4% of most recent FU endoscopy cases. This is comparable to 63.8% at diagnosis and remains in line with the upper estimates (36%-66%) of the presence of granulomatous disease (17, 18) .
At all FU points there remains a significant proportion of patients with UC (27.3%-33.3%) with inflammatory gastritis, previous studies have demonstrated this at diagnosis and here we detail a persistence through FU (19, 20) . Upper GI involvement remains more common in CD, with a 55.3% to 78.7% of patients having histologically confirmed gastric inflammation at FU.
Van Limbergen et al (21) detailed the 2-year endoscopic FU of patients with PIBD, finding 39% of patients had an extension of disease during this time frame. In CD, L3 disease was present in 16.3% of cases with L3 þ L4A disease present in 43.9% at 2-year FU. Our study reports 6.5% of patients had L3 disease and 21% had L3 þ L4A disease. In patients with UC, 82.2% had extensive disease (E3 on Montreal classification, E4 on PC), in our study 20% of patients had E4 disease at initial FU. Vernier-Massouille et al (11) also described disease extension in 31% of paediatric patients with CD in 2008. It may be that the apparent reduction in disease extent during FU during this 10-year period is due to more aggressive immunosuppression and the increasing use of biological therapies as directed by ESPGHAN/NASPGHAN guidelines (22, 23) . In comparison to Van Limbergen et al's study there was introduction of immunomodulatory agents at an earlier time point in this study with only 46% of children with CD on these medication within 1 year compared to 71.6% in this study. Rinawi et al (24) demonstrated 28% of CD patients progressing to more extensive macroscopic disease over a 10-year FU period, although microscopic disease extent was not reassessed it's presence at diagnosis appeared to be associated with more macroscopic disease extension during FU.
Although the PC of disease remains an important and validated tool for classification of disease, it only accounts for endoscopic disease extent. The data presented here make a further case for the inclusion of histological disease extent in a modified PC (and therefore a modified Montreal classification). In CD there is a persistent and statistically significant difference between the classical PC and the modified (histological) classification, characterized by increased extensive disease (L3 þ L4A) and upper GI involvement. There is a greater discrepancy at FU between classical and modified histological PC (Table 3) . If mucosal healing is the aim of therapy then it is vital that patients are not ''underclassified'' based on endoscopic findings only as this may lead to undertreatment. The role of histological disease extent on disease phenotype, progression, and outcome remains uncertain and prospective longitudinal cohort studies are vital to provide an evidence base for the ultimate goal of treatment (endoscopic vs histological vs transmural healing). Additional consideration of the role of transmural healing in CD must be made through future studies, in addition to assessing outcome compared to mucosal and macroscopic healing.
Patients were studied at diagnosis and FU utilizing prospectively entered data collected. All uncertain results were discussed contemporaneously at a multidisciplinary meeting of paediatric gastroenterologists and paediatric pathologists; however, interobserver bias cannot be completely excluded from the present study and is a potential weakness. In addition there will be an intrinsic bias towards inclusion of more extensive disease in this study as those patients with worse disease/symptoms are more likely to undergo repeat endoscopy. All endoscopies were performed by a team of 4 consultant paediatric gastroenterologists using a structured biopsy system. The present study focuses on disease extent as described through endoscopy and histology, PC requires small bowel imaging to fully assess disease distribution; however, this study does not include small bowel disease diagnosed by capsule endoscopy or radiological imaging where histological evidence of disease is not simultaneously available.
CONCLUSIONS
The present study provides new data detailing the location of disease in PIBD during a 3-year FU period. Histological disease extent remains greater than endoscopic disease extent throughout FU and the discrepancy increases in CD, but there is no significant difference in UC or IBDU, although fewer patients were studied. The present study suggests that as histological disease extent is frequently greater than endoscopic disease extent that this should be considered when disease is classified particularly as contemporary treatment regimens are often aimed at achieving mucosal healing and long-term remission.
